Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GPCRNASDAQ:OCULNASDAQ:ORICNASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGPCRStructure Therapeutics$25.91+9.7%$20.16$13.22▼$62.74$1.47B-1.35910,987 shs486,992 shsOCULOcular Therapeutix$8.24+1.4%$7.27$4.62▼$11.78$1.31B1.491.47 million shs126,040 shsORICORIC Pharmaceuticals$5.42+6.4%$6.33$3.90▼$14.67$380.71M1.38632,685 shs99,252 shsSPRYARS Pharmaceuticals$13.95-1.3%$12.56$7.55▼$18.51$1.37B0.861.17 million shs113,498 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGPCRStructure Therapeutics-0.51%+2.25%+19.47%-18.33%-39.34%OCULOcular Therapeutix+5.45%+6.83%+7.26%+2.91%+71.34%ORICORIC Pharmaceuticals-0.20%+4.52%-17.10%-56.42%-36.93%SPRYARS Pharmaceuticals+2.69%-1.26%+13.21%-4.97%+69.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGPCRStructure Therapeutics2.2165 of 5 stars3.51.00.00.03.31.70.6OCULOcular Therapeutix3.6062 of 5 stars3.41.00.04.13.41.70.0ORICORIC Pharmaceuticals3.8786 of 5 stars3.52.00.04.32.11.70.6SPRYARS Pharmaceuticals3.1732 of 5 stars3.62.00.00.03.14.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGPCRStructure Therapeutics 3.00Buy$81.29213.72% UpsideOCULOcular Therapeutix 2.89Moderate Buy$16.3898.70% UpsideORICORIC Pharmaceuticals 3.00Buy$18.86248.24% UpsideSPRYARS Pharmaceuticals 3.17Buy$31.00122.16% UpsideCurrent Analyst Ratings BreakdownLatest ORIC, SPRY, GPCR, and OCUL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/8/2025OCULOcular TherapeutixWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/8/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/20/2025ORICORIC PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.003/18/2025OCULOcular TherapeutixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$17.003/11/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.003/7/2025SPRYARS PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$30.003/4/2025OCULOcular TherapeutixJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.003/4/2025OCULOcular TherapeutixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/3/2025SPRYARS PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/28/2025GPCRStructure TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGPCRStructure TherapeuticsN/AN/AN/AN/A$9.77 per shareN/AOCULOcular Therapeutix$63.72M20.57N/AN/A$0.79 per share10.43ORICORIC PharmaceuticalsN/AN/AN/AN/A$3.42 per shareN/ASPRYARS Pharmaceuticals$89.15M15.36N/AN/A$2.40 per share5.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGPCRStructure Therapeutics-$89.62M-$0.79N/AN/AN/AN/A-16.37%-15.68%5/8/2025 (Estimated)OCULOcular Therapeutix-$80.74M-$1.26N/AN/AN/A-283.74%-45.18%-30.87%5/6/2025 (Estimated)ORICORIC Pharmaceuticals-$100.70M-$1.82N/AN/AN/AN/A-44.54%-40.72%5/5/2025 (Estimated)SPRYARS Pharmaceuticals-$54.37M$0.08N/AN/AN/AN/A-22.56%-21.82%5/8/2025 (Estimated)Latest ORIC, SPRY, GPCR, and OCUL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GPCRStructure Therapeutics-$0.24N/AN/AN/AN/AN/A5/8/2025Q1 2025SPRYARS Pharmaceuticals-$0.35N/AN/AN/A$7.48 millionN/A5/6/2025Q1 2025OCULOcular Therapeutix-$0.28N/AN/AN/A$17.02 millionN/A5/5/2025Q1 2025ORICORIC Pharmaceuticals-$0.52N/AN/AN/AN/AN/A3/20/2025Q4 2024SPRYARS Pharmaceuticals-$0.04$0.52+$0.56$0.52$15.46 million$86.58 million3/3/2025Q4 2024OCULOcular Therapeutix-$0.24-$0.29-$0.05-$0.29$16.89 million$17.08 million2/27/2025Q4 2024GPCRStructure Therapeutics-$0.23-$0.22+$0.01-$0.22N/AN/A2/18/2025Q4 2024ORICORIC Pharmaceuticals-$0.52-$0.51+$0.01-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGPCRStructure TherapeuticsN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/AORICORIC PharmaceuticalsN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGPCRStructure TherapeuticsN/A27.6327.63OCULOcular Therapeutix0.1913.0112.94ORICORIC PharmaceuticalsN/A10.5613.15SPRYARS PharmaceuticalsN/A12.5612.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGPCRStructure Therapeutics91.78%OCULOcular Therapeutix59.21%ORICORIC Pharmaceuticals95.05%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipGPCRStructure Therapeutics9.43%OCULOcular Therapeutix3.50%ORICORIC Pharmaceuticals5.55%SPRYARS Pharmaceuticals40.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGPCRStructure Therapeutics13657.34 million51.86 millionOptionableOCULOcular Therapeutix230159.02 million151.71 millionOptionableORICORIC Pharmaceuticals8071.03 million67.09 millionOptionableSPRYARS Pharmaceuticals9098.12 million58.21 millionOptionableORIC, SPRY, GPCR, and OCUL HeadlinesRecent News About These CompaniesARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Buy" from AnalystsApril 28 at 2:08 AM | marketbeat.comRaymond James Financial Inc. Invests $6.58 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)April 26 at 3:57 AM | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Trexquant Investment LPApril 15, 2025 | marketbeat.comExodusPoint Capital Management LP Buys Shares of 24,628 ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)April 15, 2025 | marketbeat.comVanguard Group Inc. Raises Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)April 15, 2025 | marketbeat.comLaura Shawver Sells 50,002 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockApril 10, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 50,002 SharesApril 9, 2025 | insidertrades.comSei Investments Co. Invests $1.14 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)April 9, 2025 | marketbeat.comFranklin Resources Inc. Decreases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)April 8, 2025 | marketbeat.comAlliancebernstein L.P. Has $40.94 Million Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)April 7, 2025 | marketbeat.comARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your MoneyApril 6, 2025 | msn.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 4.9% - Should You Buy?April 4, 2025 | marketbeat.comAssuredPartners Investment Advisors LLC Takes $312,000 Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)March 30, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This YearMarch 26, 2025 | finance.yahoo.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | insidermonkey.comScotiabank Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)March 22, 2025 | markets.businessinsider.comARS Pharmaceuticals’ Earnings Call Highlights Growth and ChallengesMarch 22, 2025 | msn.comWhy ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Down 13.63%March 22, 2025 | aaii.comARS Pharmaceuticals reports FY24 EPS 8c, consensus (56c)March 21, 2025 | markets.businessinsider.comARS Pharmaceuticals expects cash to fund operations for at least next 3 yearsMarch 21, 2025 | markets.businessinsider.comARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges AwaitMarch 20, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?2 Defensive Sectors to Protect Your Portfolio During a RecessionBy Ryan Hasson | April 7, 2025View 2 Defensive Sectors to Protect Your Portfolio During a RecessionBroadcom’s Apple Relationship: AI Opportunity Meets Tariff RiskBy Leo Miller | April 17, 2025View Broadcom’s Apple Relationship: AI Opportunity Meets Tariff RiskIs Alphabet Misunderstood? Here’s Why the Bulls Are BuyingBy Ryan Hasson | April 21, 2025View Is Alphabet Misunderstood? Here’s Why the Bulls Are BuyingWhy Smart Investors Don’t Panic in Election SeasonBy Sarah Horvath | April 24, 2025View Why Smart Investors Don’t Panic in Election SeasonORIC, SPRY, GPCR, and OCUL Company DescriptionsStructure Therapeutics NASDAQ:GPCR$25.91 +2.29 (+9.70%) As of 11:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Ocular Therapeutix NASDAQ:OCUL$8.24 +0.11 (+1.37%) As of 11:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.ORIC Pharmaceuticals NASDAQ:ORIC$5.42 +0.33 (+6.39%) As of 11:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.ARS Pharmaceuticals NASDAQ:SPRY$13.95 -0.19 (-1.32%) As of 11:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Kroger: This Must-Own Staples Stock Thrives in Every Market 3M Stock: 4 Compelling Reasons to Buy, 1 Big Reason to Pass Disney: The Compelling Case for Buying Now Before They Scale Up Southwest Airlines CEO Calls Recession, Why Option Traders Jumped Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
